A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Tavilermide Ophthalmic Solution 1% Tavilermide Ophthalmic Solution |
Drug: 1% Tavilermide Ophthalmic Solution
1% Tavilermide BID Dosing
|
Placebo Comparator: Vehicle Ophthalmic Solution Placebo Ophthalmic Solution |
Drug: Placebo Ophthalmic Solution
Vehicle Ophthalmic Solution
|
Outcome Measures
Primary Outcome Measures
- Total Corneal Fluorescein Staining Using The Ora Calibra Scale [Day 57]
An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE)
- Ocular Discomfort Using The Ora Calibra Scale [Day 57]
A patient-reported subjective assessment of ocular discomfort recorded at each of the 5 office visits throughout the treatment period
Secondary Outcome Measures
- Total Corneal Fluorescein Staining Using The Ora Calibra Scale [Day 15]
An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE)
- Ocular Surface Disease Index [Day 57]
- Ocular Dryness Using The Ora Calibra Scale [8 weeks]
A patient-reported subjective assessment of ocular dryness recorded twice daily over the complete treatment period.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Be at least 18 years of age.
-
Provided written informed consent.
-
Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye
Exclusion Criteria:
- Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit
-
Be diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months.
-
Have any planned ocular and/or lid surgeries over the study period.
-
Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit .
-
Have an uncontrolled systemic disease.
-
Be a woman who is pregnant, nursing or planning a pregnancy.
-
Be a woman of childbearing potential who is not using an acceptable means of birth control
-
Have a known allergy and/or sensitivity to the test article or its components.
-
Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
-
Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | MIM-726 Investigational Site | Torrance | California | United States |
Sponsors and Collaborators
- Mimetogen Pharmaceuticals USA, Inc.
Investigators
- Study Director: Garth Cumberlidge, PhD, Mimetogen Pharmaceuticals USA, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MIM-726